10 completed, 4 unknown, 3 recruiting, 1 not yet recruiting. 4 Phase 2, 4 Phase 3, 4 Phase 4, 3 Phase 1, 2 Not applicable.
Follow Piebaldism: new trials by email Literature Review of Piebaldism trials Research Report on Piebaldism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment physician-selected treatment, Regorafenib + Envafolimab - GIST - Gastrointestinal Stromal Tumor, KIT Gene Mutation | Phase 2 | Recruiting | Jian Li | 100 | 2025-07-14 | 2026-04-30 |
| A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit NN3201 - Gastrointestinal Stromal Tumors, Small-cell Lung Cancer | Phase 1 | Recruiting | Novelty Nobility, Inc. | 67 | 2025-02-03 | 2025-09-23 |
| Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST Imatinib Mesylate, Local resection - Gastrointestinal Stromal Tumor of Rectum | Phase 3 | Not yet recruiting | Fujian Medical University Union Hospital | 23 | 2023-10-01 | 2023-08-01 |
| Korean Translation and Validation of the K-HEPI in NYC Nurses Taking On Readiness Measures (N- TORM) - Disaster, Vulnerable Populations | Not applicable | Completed | Hunter College of City University of New York | 400 | 2023-07-13 | 2024-08-15 |
| Nurses Taking On Readiness Measures - Mercer County, New Jersey Nurses Taking On Readiness Measures (N-TORM) - Disaster, Vulnerable Populations | Not applicable | Completed | Hunter College of City University of New York | 31 | 2022-03-07 | 2024-12-05 |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Unknown | AB Science | 140 | 2020-07-01 | 2023-05-06 |
| Japanese OMI Treatment With Kit-positive Cells for Enhanced Regeneration Stem cells administered to participants - Chronic Heart Failure, Old Myocardial Infarction | Phase 1 | Unknown | Sakakibara Heart Institute | 6 | 2017-11-15 | 2021-03-18 |
| Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients ReCell, Full surface CO2 laser 200 mJ, Full surface CO2 laser 150 mJ - Segmental Vitiligo, Piebaldism | Phase 4 | Completed | Netherlands Institute for Pigment Disorders | 10 | 2015-05-01 | 2017-04-04 |
| Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. ponatinib hydrochloride, laboratory biomarker analysis - Malignant Neoplasm | Phase 2 | Completed | Sameek Roychowdhury | 22 | 2015-02-24 | 2025-03-24 |
| Evaluation of Non-cultured Epidermal Cellular Grafting vs Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism VITICELL, PLACEBO - Vitiligo, Piebaldism | Phase 3 | Completed | Laboratoires Genévrier | 38 | 2014-04-29 | 2019-10-14 |
| Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study Nilotinib - Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST) | Phase 4 | Completed | Novartis Pharmaceuticals | 57 | 2013-03-29 | 2024-02-08 |
| Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients ReCell epidermal cell suspension grafting, CO2 laser abrasion + UV-therapy - Piebaldism, Segmental Vitiligo | Phase 4 | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 10 | 2012-06-01 | 2013-08-05 |
| Punchgrafting Techniques for Vitiligo punchgrafting - Non-segmental Vitiligo, Segmental Vitiligo | Phase 4 | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 35 | 2011-06-01 | 2011-06-21 |
| Allergy and Immunology Natural History Study Immune Deficiency, Immune Dysregulation Disorder | Recruiting | Columbia University | 10000 | 2010-07-16 | 2026-02-04 | |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Completed | AB Science | 135 | 2008-12-01 | 2019-12-03 |
| Molecular Mechanisms and Diagnosis of Mastocytosis Collection of blood and bone marrow - Mastocytosis | Completed | University of Michigan | 136 | 2004-07-01 | 2016-11-07 | |
| A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia Imatinib (Gleevec) - Leukemia | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 35 | 2004-07-01 | 2015-06-24 |
| A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene Imatinib mesylate - Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST) | Phase 2 | Completed | Novartis Pharmaceuticals | 148 | 2000-06-01 | 2014-08-19 |
Gastrointestinal Stromal Tumors (5) · Mastocytosis (3) · Vitiligo (3) · Anaphylaxis (2) · Blushing (2) · Emergencies (2) · Mastocytosis, Systemic (2) · Pruritus (2) · Angioedema (1) · Asthma (1) · Autoimmune Diseases (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Renal Cell (1) · Dermatitis, Atopic (1)
Albinism (18) · Amino Acid Metabolism, Inborn Errors (18) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18) · Eye Diseases, Hereditary (18) · Genetic Diseases, Inborn (18) · Hypopigmentation (18) · Metabolic Diseases (18) · Metabolism, Inborn Errors (18) · Nutritional and Metabolic Diseases (18) · Pigmentation Disorders (18) · Skin Diseases (18) · Skin Diseases, Genetic (18) · Skin and Connective Tissue Diseases (18) · Neoplasms (9) · Neoplasms by Histologic Type (9)
Imatinib Mesylate (3) · masitinib (2) · Mastectomy, Segmental (1) · envafolimab (1) · nilotinib (1) · ponatinib (1) · regorafenib (1)
AB Science (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Hunter College of City University of New York (2) · Novartis Pharmaceuticals (2) · Columbia University (1) · Fujian Medical University Union Hospital (1) · Jian Li (1) · Laboratoires Genévrier (1) · Netherlands Institute for Pigment Disorders (1) · Novelty Nobility, Inc. (1) · Sakakibara Heart Institute (1) · Sameek Roychowdhury (1) · University Health Network, Toronto (1) · University of Michigan (1)
United States (9) · Netherlands (5) · France (4) · Canada (2) · China (2) · Italy (2) · Russia (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Finland (1) · Germany (1) · Hong Kong (1) · Hungary (1)
Albert Wolkerstorfer, MD, PhD (1) · Cem Akin, M.D., Ph.D. (1) · Cristina Bulai Livideanu, MD, MSc (1) · Jian Li, MD (1) · Joshua D. Milner, MD (1) · Menno A. De Rie, MD, PhD (1) · Nanja Van Geel, Pr (1) · Olivier Lortholary, MD, PhD (1) · Sameek Roychowdhury, MD, PhD (1) · Sunil Sharma, MD (1) · Tara Heagele, PhD, RN (1) · Tara N Heagele, PhD (1) · Weizhong Jiang, MD (1)
2016 (1)